The effect of vasoactive peptides on vascular smooth muscle in the cerebral microcirculation was ex amined using an isolated intracerebral arteriole prepara tion. Extraluminally applied vasoactive intestinal peptide (VIP) dilated the spontaneous tone of intracerebral arte rioles to 118.9 ± 3.1% of control diameter at pH 7.30, with an EC50 of 7.27 x 10-8 M. Similar degrees of dila tion to VIP were seen in vessels preconstricted by changing bath solution to pH 7.60. Substance P had no effect on vessel diameter at pH 7.30. However, in vessels precontracted by pH 7.60, significant dose-dependent di lation was observed with an EC50 of 2.55 x 10-1 0 M.
Summary:
The effect of vasoactive peptides on vascular smooth muscle in the cerebral microcirculation was ex amined using an isolated intracerebral arteriole prepara tion. Extraluminally applied vasoactive intestinal peptide (VIP) dilated the spontaneous tone of intracerebral arte rioles to 118.9 ± 3.1% of control diameter at pH 7.30, with an EC50 of 7.27 x 10-8 M. Similar degrees of dila tion to VIP were seen in vessels preconstricted by changing bath solution to pH 7.60. Substance P had no effect on vessel diameter at pH 7.30. However, in vessels precontracted by pH 7.60, significant dose-dependent di lation was observed with an EC50 of 2.55 x 10-1 0 M.
Local chemical, neural, and humoral mecha nisms affect cerebral vascular resistance. Neural regulation of cerebral blood flow is mediated by ad renergic, cholinergic, and peptidergic mechanisms. These systems, acting either alone or in combina tion, change vessel caliber and thus change resis tance to blood flow. Adrenergic and cholinergic control of cerebral resistance vessels occurs mainly by the release of a vasoactive substance from nerve endings near the wall of the vessel. Innervation of cerebral vessels has been demonstrated both ana tomically, by histochemical methods, and physio logically by studies of vascular smooth muscle in vitro and studies of CBF regulation in vivo.
Some neural responses of the cerebral circula tion, however, are not controlled by the classical Neuropeptide Y constricted intracerebral arterioles to 8l.22 ± 2.7% of control diameter, with an EC50 of 6.23 x 10-1 0 M. Bradykinin dilated intracerebral arterioles at pH 7.30 and pH 7.60 to 130 ± 3.0% of control diameter. VIP and bradykinin are potent vasodilators of intracerebral arterioles. Neuropeptide Y is a vasoconstrictor. The ef fect of substance P appeared to be either pH-dependent or dependent on some degree of precontraction by an other agonist, but no effect on vessel diameter was seen at pH 7.30. Key Words: Arterioles-Cerebral microcir culation-Kinins-Rat-Vascular smooth muscle-Va soactive peptides.
adrenergic and cholinergic mechanisms of the auto nomic nervous system. These responses are con trolled by nerves that employ peptides as the va soactive transmitter substance and by parenchymal cells that produce vasoactive peptides in tissue sur rounding cerebral vessels (Edvinsson, 1985) . The presence of peptidergic nerves has been demon strated anatomically with immunohistochemical methods, and their functional importance has been shown by studies of their effect on vascular smooth muscle (Y SM) in vitro and CBF in vivo. Of the peptides released from perivascular nerves (pre sumably those of the greatest functional signifi cance), the most widely studied are vasoactive in testinal peptide (YIP), substance P, and neuropep tide Y. Bradykinin is a prominent humoral peptide implicated in vessel injury, inflammation, and func tional regulation of the cerebral vasculature (Wahl et al., 1983a; Edvinsson, 1985) . This study focuses on the effect of neuropeptides on intracerebral arterioles. These arterioles are bathed in brain interstitial fluid, and because of their proximity to neural parenchyma and intrinsic peptidergic neural pathways, their reactivity to peptidergic transmitters is important for an under-standing of the role of these transmitters in control of cerebral blood flow.
Our specific aims in this study, therefore, were (1) to determine the response of intracerebral arte rioles in vitro to VIP, substance P, neuropeptide Y, and bradykinin; (2) to determine the interaction of these peptides with local chemical control mecha nisms (H+); and (3) to relate the in vitro responses made by intracerebral arterioles to these neuropep tides to the responses made in vitro by larger resis tance vessels, as well as to in vivo responses in ce rebral blood flow. As responses to other vasoactive substances vary with size and position of the vessel in the cerebrovascular tree, similar effects of vessel location might also be expected with these pep tides.
MATERIALS AND METHODS

Isolation and cannulation of vessels
Animal experimentation was conducted in conformity with the Guiding Principles in the Care and Use of An imals. Penetrating intacerebral arterioles were isolated and cannulated in an organ bath, and changes in vessel diameter in response to the extraluminal administration of agents were measured, as described in detail pre viously (Duling et aI., 1981; Dacey and Duling, 1982) . Briefly, penetrating arterioles, 30-70 f.Lm in diameter, were surgically isolated from the first (M -1) portion of the middle cerebral artery from the brains of pentobarbital anesthetized Sprague-Dawley rats weighing 300-400 g. The vessel segments were transferred to a temperature controlled chamber on the stage of a Nikon inverted mi croscope and were cannulated using glass pipettes. Vessel diameter and wall thickness were determined using a videodimensional analysis system (modified Col orado Video, Model 321).
After vessel cannulation, transmural pressure was set at 60 mm Hg via the cannulating pipette and was main tained constant throughout the experimental protocol. Bath temperature was brought to 37-38°C, and vessels were allowed to equilibrate over a period of approxi mately 45 min at an extraluminal bath solution pH of 7.30. Bath solution was changed 2 or 3 times during the equilibration period. The vessels developed spontaneous tone during this time, contracting to approximately 70% of maximal passive diameter. Responsiveness of the vessels was then assessed by changing the extraluminal pH from 7.30 to 7.60 and from 7.30 to 6.80.
Perfusion and bath solutions
The physiological salt solutions used in this prepara tion were modified Ringer's solutions whose composi tions were as follows (in mM): NaCI 144, KCl 3.0, CaCl2 2.5, MgS04 1.5, glucose 5, pyruvate 2.0, ethylenedi aminetetraacetic acid (EDTA) 0.02, 3-[N-morpholinol propane sulfonic acid (MOPS) 2.0, NaH2P04 1.21, bovine serum albumin 0.9-1 g/dl. Intraluminal solution pH was maintained at 7.30 for all experiments. The extraluminal solution contained no albumin, and the pH was varied from 6.80 to 7.60.
Bradykinin ( 
Determination of peptide dose-response curves
Control vessel diameter was defined as the diameter to which the vessels spontaneously contracted during the equilibration period in a bath solution of pH 7.30. Bath solutions of increasing peptide concentration were added sequentially to the cannulation chamber. Approximately 5 ml of solution was flushed through the 1.3-ml chamber with each solution change. The pH of each solution of increasing peptide concentration was checked prior to in stillation into the chamber and was found not to vary sig nificantly from pH 7.30. Vessel diameter was monitored for 4-5 min after each bath change. Responses of pene trating intracerebral arterioles to bradykinin, substance P, vasoactive intestinal peptide (VIP), and neuropeptide Y were determined at a bath solution pH of 7.30.
Dose-response curves at pH 7.60 were determined in a similar manner. The control diameter in this portion of the experiment was the same as that achieved in physio logical salt solution at pH 7.30. Before addition of any peptide to the organ bath, solution pH of the extraluminal bath fluid was raised to 7.60, and vessel diameter was allowed to equilibrate at a new, constricted diameter for approximately 5 min. Solutions of increasing peptide concentration in physiological salt solution at pH 7.60 were then administered in the same manner as for pH 7.30, and the pH of each peptide solution was checked prior to instillation in the bath and was found not to vary from pH 7.60.
Statistical analysis
Group mean diameters for each agonist dose, ex pressed as a percent of initial (control) vessel diameter, were compared by one-way analysis of variance (AN OVA) (Zar, 1974.) Differences between group mean diameters were compared with Student-Newman-Keuls (Zar, 1974) multiple range tests for significant ANOVAs. Null hypotheses were rejected at a probability of 0.05 or less. Values are expressed as mean ± 1 SEM. Agonist concentrations at which half-maximal responses were obtained (EC50) were calculated by the method of Ta l larida and Murray (1987) . Briefly, probit-transformed vessel diameters were regressed linearly against the loga rithm of agonist dose for each vessel tested. Mean log EC50 values and intervals of mean log EC50 ± 1 SEM were calculated for all vessels tested with a given agonist. Retransformed mean EC50 values and mean ± 1 SEM in tervals are reported for all agonists showing significant dose-response effects.
RESULTS
Effect of VIP on in vitro arteriolar reactivity
At an extraluminal solution pH of 7.30, VIP sig nificantly (p = < 0. 001) dilated intacerebral arte rioles in a dose-dependent manner, reaching 118. 9 ± 3. 1% of control diameter (60. 4 ± 4. 1 mm) at a dose of 3 x 10-7 M (Fig. 1 ). Threshold dose of VIP at pH 7. 3 was 10-10 M, and EC5 0 was 7. 27 x 10-9 M (3. 94 x 10-9-1. 34 x 10-8 M). No preactivation M 13 ,..:
-L P�6 10. 12 10'" 10. 10 10'9 10'· 10.7 10'- of the vascular smooth muscle was necessary to obtain arteriolar dilation; VIP released the sponta neous tone developed by the vessel during the equilibration period. In addition, at doses higher than 3 x 10-7 M, arteriolar constriction was found.
At an extraluminal solution pH of 7.60, VIP also significantly (p < 0.00 1) dilated intracerebral arte rioles in a dose-dependent manner. Arteriolar diam eter was reduced to 79.2 ± 3.4% of control diam eter (56.4 ± 5.2 mm) when extraluminal solution pH was increased from 7.30 to 7.60. Vessel diam eter then increased with each increasing VIP dose, reaching a maximum of 102.7 ± 2.6% of control diameter at 3 x 10-7 M. Threshold VIP dose was 10-12 M, and EC5 0 was 3.59 x 10-10 M (1.60 x 10-10_8.06 x 10-10 M). Removal of VIP from the extraluminal fluid at pH 7.60 caused constriction of the arterioles, with diameter returning toward its initial level, reaching 89. 1 ± 3.7% of control.
VIP dilated intacerebral arterioles by 20% of control diameter at both in situ pH of 7.30 and with external smooth muscle activation at pH 7.60. At pH 7.60, however, the threshold dose was lower than that observed at pH 7.30 (10-12 M versus 10 -10 M), and EC5 0 was also significantly lower (p < 0.05) than that observed at pH 7.30 (3.59 x 10-10 M versus 7.27 x 10-9 M). Intracerebral arterioles exhibited greater sensitivity to extraluminally ap plied VIP when constricted to diameters less than those that develop spontaneously at pH 7.30. Nev ertheless, the ultimate amount of dilation obtained was not affected by the application of an external constrictor agent.
Effect of substance P on in vitro arteriolar reactivity
Spontaneously developed arteriolar tone was not significantly altered by extraluminally applied sub- Points represent mean ± SEM vessel diameters expressed as percent of control diameter. No significant change in diam eter occurred at pH 7.30, but it was observed at pH 7.60.
stance P at a solution pH of 7.30 ( Fig. 2) . Vessel diameter varied between 96.2 ± 4.6% and 106.9 ± 3.7% of control diameter (39.6 ± 5.9 mm) when the dose of extraluminally applied substance P was varied from 10-12 M to 10-4 M. Although not sig nificant, a trend toward vessel contriction was found when the substance P dose was increased from 10-6 to 10-4 M at the high end of the dose response curve. At a bath solution pH of 7.60, however, sub stance P significantly (p < 0.05) dilated intracerebral arterioles in a dose-dependent manner. Increasing solution pH from 7.30 to 7.60 constricted arterioles to 79.2 ± 2.3% of control diameter (49.9 ± 7.1 mm). Sequential addition of increasing substance P doses, beginning at 10 -12 M, dilated the vessels to 93.4 ± 3.4% of control diameter at 10-6 M. Subse quent addition of 10-4 M substance P at pH 7.6 constricted the vessels in a manner similar to that seen at pH 7.30. Threshold dose of substance P was 10-1 2 M, and EC5 0 was 2.55 x 10-10 M (1.30 x 10-10-5.00 x 10-10 M). Removal of substance P and return of the bath solution to pH 7.60 con stricted the vessels to 82.2 ± 2.7% of control diam eter, which was not significantly different from the diameter before the dose-response curve was de termined.
Effect of neuropeptide Y on in vitro arteriolar reactivity
At an extraluminal solution pH of 7.30, neuro peptide Y significantly (p < 0.001) constricted in tracerebral arterioles in a dose-dependent manner, reaching 81.2 ± 2.7% of control diameter (51.5 ± 7.6 mm) at a dose of 10-8 M (Fig. 3) . Threshold dose was 10-11 M, and EC5 0 was 6.23 (4. 17 X 10-1 0 -9.31 X 10-1 0 M). As neuropeptide Y dose was increased to 10-7 M, a reversal of the constrictor effect was seen.
Effect of bradykinin on in vitro arteriolar reactivity
At a bath solution pH of 7. 30, bradykinin re leased spontaneously developed arteriolar tone in a dose-dependent manner (Fig. 4) . The increase in vessel diameter was not statistically significant, due to the large variation encountered responses of in dividual vessels at bradykinin doses above 10-8 M. At pH 7.30, bradykinin dilated arterioles to 130 ± 12. 0% of control diameter (54. 0 ± 6.2 mm) at a dose of 10-6 M, with a threshold dose of 10-11 M and an apparent EC5 0 of 1.63 X 10-8 M (7.69 x 10-9-2. 90 x 10-7 M).
At a bath solution pH of 7.60, bradykinin signifi cantly (p < 0. 00 1) dilated arterioles in a dose-de pendent manner. Elevation of solution pH from 7. 30 to 7.60 constricted vessel diameter to 75. 5 ± 2. 1% of control diameter (6 1. 9 ± 3.9 mm). Subse quent addition of solutions of increasing bradykinin concentration at pH 7.60 dilated intracerebral arte rioles, reaching 99.8 ± 3. 7% of control diameter at a BK dose of 8 x 10-6 M. Threshold dose of bra dykinin was 10-11 M, and EC5 0 was 9.02 x 10-9 M (4.92 x 10-9-1.65 x 10-8 M).
Solution pH appeared to have little effect on the response of intracerebral arterioles to bradykinin. Threshold dose was comparable (10-11 M) at both pHs, and EC5 0 also was not significantly different (1.63 x 10-8 M at pH 7.30 versus 9.02 x 10-9 M at pH 7. 60. ). In addition, arterioles dilated a compa rable amount (25-30% of control diameter) with in creasing bradykinin dose. Maximal dilation was found at 8 x 10-7 M bradykinin at pH 7.30 and at 8 x 10-6 M bradykinin at pH 7. 60. Changing solu- tion pH appeared to alter the diameter at which the arteriole functioned without affecting the vessel's response to bradykinin.
DISCUSSION
Vasoactive intestinal peptide (VIP)
In the present study, VIP dilated both intracere bral arterioles with spontaneous tone and those pre contracted by pH 7.60. VIP was first noted to be a vasodilator in the cerebral circulation by McCul loch and . The degree of dilation (approximately 20%) elicited by VIP in these intra parenchymal vessels was similar to that reported by Wei et al. (1980) in cat pial arteries. The use of in vitro techniques in this study circumvented the ap parent effect of the blood-brain barrier on intraar terially administered VIP (Wilson et aI. , 198 1) and indicated that vessels very distal in the cerebral mi crocirculation are sensitive to VIP. These vessels could be affected by VIP, which originates in peri vascular nerves or as an extracellular space neuro transmitter in cortical neurons (Eckenstein and Baughman, 1984) . Our data also indicate that cere bral vessels are quite sensitive to VIP (as compared with pial vessels) (McCulloch and .
Current knowledge of the role of VIP in the cere bral circulation was summarized by Duckles (1983) , Busija and Heistad (1984) , Hardebo et al. (1984) , Wahl (1985) , and Kobayashi et al. (1985) . The pres ence of this 28 amino acid peptide in nerves inner vating cerebral vessels has been demonstrated im munohistochemically and by radioimmunoassay. Fibers containing VIP have been found to be asso ciated with vessels up to the level of penetrating arterioles, but not at the level of capillaries. These fibers are localized within the arterial vessels to the medial-adventitial border, where, as recently dem onstrated by Itakura et ai. (1986) , they end on the inner layers of the adventitia in a spiral pattern. VIP has also been shown to be co-localized in cere bral tissues with choline acetyltransferase in nerves that are thought to be responsible for neurogenic cerebral vasodilation (Eckenstein and Baughman, 1984) . In addition, sympathectomy does not reduce the presence of VIP in pial arteries as measured by immunofluorescence (Edvinsson et aI., 1984) .
VIP relaxes cerebrovascular smooth muscle in vitro with or without an intact endothelium (Huang and Rorstad, 1984) . Perivascular application of VIP to pial arteries in vivo also produces a dose-depen dent vasodilation that is blocked by cyclooxy genase-inhibitor products in cat pial arteries and is not mediated by superoxide radicals (Wei et aI., 1980; BaIlon et aI., 1986) . Relaxation of cerebrovas cular smooth muscle by VIP is also mediated by binding to a receptor on the smooth muscle cell that stimulated adenylate cyclase. Edvinsson et ai. (1985) showed that VIP-induced dilation of cerebral arteries is accompanied by the accumulation of cy clic adenosine monophosphate (c-AMP) in smooth muscle cells, and Huang and Rorstad (1984) found that VIP receptors in cerebral arteries and micro vessels are coupled to adenylate cyclase. A similar action mechanism for VIP was demonstrated in the mesenteric circulation by Gantz et ai. (1986) .
Exogenous VIP administered intraarterially or intraventricularly increased cerebral blood flow in situations in which cerebral metabolic rate was ei ther increased or remained unchanged (Heistad et aI., 1980; Larsen et aI., 1981; McCulloch and Ed vinsson, 1984) . As mentioned previously, VIP has been anatomically co-localized with choline acetyl transferase in nerves responsible for neurogenic va sodilation in the cranial and extracranial vascula ture. McCulloch et ai. (1983) have also shown that VIP injected into caudate nucleus causes highly focal increases in regional 2-deoxy-[14C]glucose uti lization. Bevan et ai. (1984) also demonstrated in vitro that VIP activity was highest in vessels from the circulations within the brain that exhibit neuro genic vasodilation. In addition, in in vitro studies, Lee et ai. (1984) demonstrated relaxation of feline cerebral arterial rings by VIP and that a VIP-like substance is present in large granular vesicles of nerve axons and terminals in cerebral arterial walls. Finally, Goadsby and MacDonald (1985) found that antisera to VIP blocked neurogenic vasodilation in the extracranial circulation having central stimula tion.
J Cereb Blood Flow Metab, Vol. 8, No.2, 1988 Substance P Substance P had no effect in our study on the di ameter of intacerebral arterioles that had developed spontaneous tone in bath solution pH of 7.30. This physiological observation may reflect the decrease in substance P receptor density as one progresses more distally in the cerebral microcirculation (Ed vinsson et aI., 1983b; Matsuyama et aI., 1984) . Ed vinsson et ai. (198 1) found dilation in middle cere bral artery ring segments and pial arteries and arte rioles with diameters of about 140 f1m. However, in intacerebral arterioles precontracted by pH 7,60, a modest but significant dilation was observed. This pattern of responsiveness, where precontraction is necessary for vasodilation to occur, is similar to that observed by us for acetylcholine (Dacey and Bassett, 1987) .
The role of substance P in the cerebral circula tion was recently reviewed by Duckles (1983 ), Har debo et ai. (1984 , Busija and Heistad (1984) , Wahl (1985) , and Kobayashi et ai. (1985) . By means of immunohistochemical techniques, substance P has been localized in plexuses of nonmyelinated nerve fibers surrounding cerebral arterial vessels, al though these only consist of a few fibers per cir cumference. Nerves containing substance P have also been shown to innervate other vascular beds, Substance P-containing fibers that innervate cere bral vessels arise in the trigeminal ganglion and are best characterized as primary sensory afferents in volved in nociception (Mayberg et aI., 198 1; Duckles, 1983; Lui Chen et aI., 1983) . Capsaicin re duces the substance P content of these nerve fibers and leads to their degeneration (Duckles and Buck, 1982) . Although the role of primary sensory af ferents in the cerebral circulation is a matter of speculation, these fibers appear to mediate vascular headache pain and reactions to trauma. Their origin in the trigeminal ganglion may also help explain the hemicranial distribution of headaches associated with stroke and migraine.
Recently, Uddman et ai. (1985) and Matsuyama et ai. (1986) found substance P to be co-localized with calcitonin gene-related peptide (CGRP) in nerve fibers surrounding cerebral vessels and in cell bodies in the trigeminal ganglion. The presence of both substance P and CGRP in single nerve fibers may provide increased variability of response in the sensory afferent system putatively involved in the transmission of intracranial pain.
Substance P relaxes cerebral arteries in vitro, and this vasodilator action can be blocked with peptide analogs (Edvinsson et aI., 198 1, 1982) . Peri vascular application of substance P to pial arteries and veins causes a dose-dependent vasodilation in vivo, and stimulation of fibers containing substance P results in dilation of cerebral vessels and an in crease in CBF (Hardebo et aI., 1984) . Substance P may also enhance CBF by increasing metabolism. The in vivo actions of substance P occur when sen sory nerve stimulation leads to antidromic release of substance P from perivascular fibers (Hagermark et aI., 1978) . The work of Klugman et al. (1980) suggests that substance P increases hypothalamic blood flow via the release of endogenous acetyl choline, which in turn stimulates and intacerebral noradrenergic pathway.
Relaxation of vascular smooth muscle appears to be a direct action of the peptide on muscle cells mediated by specific receptors. Smooth muscle re laxation caused by substance P is not accompanied by an increase in cellular c-AMP (Edvinsson et aI., 1985) . In contrast, relaxations caused by both CGRP and VIP are accompanied by an increase in cellular c-AMP, and the vasodilator action of sub stance P depends on the presence of an intact endo thelium, whereas the dilations produced by VIP and CGRP persist when the endothelium is re moved (Edvinsson et aI., 1985) . Differences in the mechanism of action of VIP and substance P are also mirrored in the location of nerve endings for each peptide within the blood vessel wall. Itakura et al. (1986) have shown that substance P-con taining fibers end in a meshwork pattern on the outer layers of the adventitia, whereas VIP fibers end in a spiral pattern on the inner layers. Differ ences between VIP and substance P in mechanism of action, anatomic location within the arterial wall, and nerve fiber type may indicate that substance P may not have a vasomotor function in the cerebral circulation, but that it may play a role in the media tion of nociception although the evidence of the axon reflex indicates that substance P may be in volved in both processes.
N europeptide Y
Neuropeptide Y is a potent constrictor of intrace rebral arterioles. Diameter reductions of approxi mately 20% were observed with an ED 5 0 to 6. 23 X 10-10 M. These vessels appear to be somewhat more sensitive to neuropeptide Y than the pial arte rioles studied by Edvinsson et al. (1984 Edvinsson et al. ( , 1987 , de spite the somewhat sparser immunocytochemical staining for neuropeptide Y in intracerebral vessels (Edvinsson, 1985) . The reactivity of intracerebral vessels to neuropeptide Y contrasts with reactivity to norepinephrine; penetrating arterioles studied at pH 7.30 do not respond to norepinephrine (Dacey and Duling, 1984) . These findings suggest that sym pathetic vasoconstriction in the most distal segment of the cerebral microcirculation may be mediated not by norepinephrine but by neuropeptide Y at rel atively lower perivascular concentrations.
Neuropeptide Y, a 36 amino acid peptide similar to pancreatic polypeptide, is present, as shown by immunohistochemical techniques in dense nerve fiber networks on cerebral arteries from the circle of Willis down to the penetrating arterioles (Ed vinsson et aI., 1983a (Ed vinsson et aI., , 1984 Hardebo et aI., 1984; Edvinsson, et al. 1987) . Neuropeptide Y is prob ably colocalized with norepinephrine in sympa thetic nerve terminals near cerebral vessels, as Ed vinsson et al. (1987) have demonstrated that anti bodies against dopamine beta-hydroxylase and neuropeptide Y both stain nerve cell bodies in su perior cervical ganglion and perivascular nerve fibers. Removal of the superior cervical ganglion causes loss of neuropeptide Y-like immunoreac tivity (Edvinnson et aI., 1983a (Edvinnson et aI., , 1987 . N europep tide Y seems to act at a postsynaptic site inducing contraction by a calcium-dependent mechanism (Edvinsson et aI., 1987) .
Bradykinin
Bradykinin is a potent vasodilator of intracere bral arterioles. Arterioles that had developed spon taneous tone and those precontracted by elevation of perivascular pH to 7.60 increased their diameters by approximately 30% in response to extralumi nally applied bradykinin. These vessels appear to have the same sensitivity to bradykinin as pial arte rioles (Wahl et aI., 1983; Whalley and Wahl, 1983; Unterberg and Baethmann, 1984) .
Bradykinin, the active peptide of the kallikrein kinin system, is generated, released, and degraded within the brain. It may influence cerebral resis tance vessels as well as the permeability of the blood-brain barrier. Under normal conditions, bra dykinin is produced and released in small amounts within brain parenchyma, and all enzymatic com ponents of an intacerebral kinin system are present (Wahl, 1985) .
The primary effect of bradykinin on cerebrovas cular smooth muscle is relaxation. Bradykinin re laxes cat middle cerebral arteries in vitro in a dose dependent manner, but has no effect on cat basilar arteries (Whalley and Wahl, 1983) . Bradykinin also relaxes cat and human pial arteries of all sizes in dose-dependent fashion in vitro (Wahl et aI., 1983.) In vivo, bradykinin produces a dose-dependent di lation of arteries in the pial circulation of rabbit (Kamitani et aI., 1985a, b) , mouse (Rosenblum 1986) , and cat (Wahl et al. 1983; Kontos et aI., 1984; Unterberg et aI., 1984) . The vasodilation pro duced by bradykinin is mediated by Brreceptors, which also increase blood-brain barrier perme ability and require an intact endothelium for effect (Regoli, 1984; Unterberg and Baethmann, 1984; Katusic et aI., 1986) . Vasodilation produced by bra dykinin is blocked by cyc100xygenase inhibitors, such as indomethacin and mec1ofenamate, and by free radical scavengers, such as superoxide dismu tase and catalase (Vio, et aI., 1983; Kontos et aI., 1984; Kamitani et aI., 1985a) . The vasomotor ef fects of perivascular bradykinin therefore appear to be mediated through the stimulation of prosta glandin synthesis in the vessel wall.
Bradykinin is degraded and thus inactivated in vivo by kininase I and II. In the cerebral circula tion, inactivation in kininase II by captopril or po tentiator C does not increase the activity of brady kinin in human or cat cerebral arteries in vitro or in cat pial arteries in vivo (Wahl et aI., 1983; Wahl, 1985) . These inhibitors of bradykinin breakdown, however, do potentiate the constrictor activity of bradykinin on guinea pig ileum (Wahl et aI., 1983) .
Intraarterial administration of bradykinin pro duces no vasomotor response, indicating that endo thelial cells have no receptors on their luminal sur face for bradykinin that can exert vasomotor effects (U nterberg et aI., 1984) . In addition, when cerebral blood flow (measured with microspheres) and cere bral metabolism (measured by a-v O 2 difference and blood flow) are determined with intraarterial infusion of bradykinin in goats, blood flow and me tabolism increase at the same time and by the same amount (Hoffman et aI., 1983) . Such an increase in blood flow with bradykinin administration suggests that stimulation of metabolism is solely responsible for the elevation of blood flow. Vasodilation of ce rebral vessels by bradykinin occurs with perivas cular application both in vitro and in vivo and pro vides the basis for a humoral system to regulate ce rebral vascular resistance in response to local conditions in the brain.
